330175-M
Echinomycin Streptomyces sp.
A cell-permeable Streptomyces-derived antibiotic that contains two bicyclic peptide-linked quinoxalines and acts as a sequence-specific DNA bisintercalator.
别名:
Echinomycin Streptomyces sp., NSC-13502, Quinomycin A
登录并加购，请在购物车里查看协议价、货期和发货地。
选择规格
变更视图
关于此项目
Assay:
≥98% (HPLC)
Form:
solid
Storage condition:
OK to freeze
assay
≥98% (HPLC)
form
solid
manufacturer/tradename
Calbiochem®
storage condition
OK to freeze
color
white
solubility
DMSO: 5 mg/mL
storage temp.
−20°C
InChI
1S/C51H64N12O12S2/c1-25(2)38-49(72)74-22-36(59-42(65)34-21-53-30-17-13-15-19-32(30)57-34)44(67)55-28(6)46(69)63(10)40-48(71)62(9)39(26(3)4)50(73)75-23-35(58-41(64)33-20-52-29-16-12-14-18-31(29)56-33)43(66)54-27(5)45(68)60(7)37(47(70)61(38)8)24-77-51(40)76-11/h12-21,25-28,35-40,51H,22-24H2,1-11H3,(H,54,66)(H,55,67)(H,58,64)(H,59,65)
InChI key
AUJXLBOHYWTPFV-UHFFFAOYSA-N
General description
A cell-permeable Streptomyces-derived antibiotic that contains two bicyclic peptide-linked quinoxalines and acts as a sequence-specific DNA bisintercalator. Echinomycin at 10 µM is shown to inhibit HIF-1 and Myc/Max DNA binding activities in U251 and MCF-7 nuclear extracts by >90%, while exhibiting little effect against the binding of AP-1 or NF-κB to their respective DNA targets that lack the 5′-ACGTG-3′ core structure in cell-free EMSA assays. Reversibly inhibits hypoxia-induced HIF-1 transcription activity in an HRE promoter-based reporter assay in U215 cells (EC50 = 1.2 nM) and is of no effect against SV40 promoter-driven transcription activity. Despite echinomycin′s in vitro apoptosis-inducing activity and the initial report of its in vivo antitumor effect in mice, clinical trials have not yet resulted in promising data regarding its therapeutic efficacy in cancer treatment.
Preparation Note
Following reconstitution, aliquot and freeze (-20°C.) Stock solutions are stable for up to 3 months at -20°C.
Other Notes
Park, J.Y., et al. 2008. Cell. Biol. Int.32, 1207.
Kong, D., et al. 2005. Cancer Res.65, 9047.
Chang, A.Y., et al. 1998. Cancer82, 292.
Wadler, S., et al. 1994. Cancer Chemother. Pharmacol.34, 266.
Muss, H.B., et al. 1993. Am. J. Clin. Oncol.16, 492.
Foster, B.J., et al. 1985. Invest. New Drugs3, 403.
Van Dyke, N.M., et al. 1984. Science225, 1122.
Ward, D.C., et al. 1965. Science149, 1259.
Kong, D., et al. 2005. Cancer Res.65, 9047.
Chang, A.Y., et al. 1998. Cancer82, 292.
Wadler, S., et al. 1994. Cancer Chemother. Pharmacol.34, 266.
Muss, H.B., et al. 1993. Am. J. Clin. Oncol.16, 492.
Foster, B.J., et al. 1985. Invest. New Drugs3, 403.
Van Dyke, N.M., et al. 1984. Science225, 1122.
Ward, D.C., et al. 1965. Science149, 1259.
Legal Information
CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany
Disclaimer
Toxicity: Toxic (F)
警示词
Danger
Hazard Classifications
Acute Tox. 3 Dermal - Acute Tox. 3 Inhalation - Acute Tox. 3 Oral - Repr. 2
存储类别
6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects
怎么回事？
WGK 3
闪点 (F)
Not applicable
闪点 (°C)
Not applicable